Ferguson Wellman Capital Management Inc. Invests $693,000 in Ascendis Pharma A/S $ASND

Posted by Brian Himes on Aug 30th, 2026

Ferguson Wellman Capital Management Inc. bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,600 shares of the biotechnology company’s stock, valued at approximately $693,000.

A number of other hedge funds have also recently modified their holdings of ASND. Braun Stacey Associates Inc. raised its stake in Ascendis Pharma A/S by 1.3% during the 2nd quarter. Braun Stacey Associates Inc. now owns 132,682 shares of the biotechnology company’s stock worth $35,389,000 after acquiring an additional 1,690 shares in the last quarter. Dearborn Partners LLC purchased a new stake in Ascendis Pharma A/S in the second quarter valued at $347,000. Public Employees Retirement System of Ohio boosted its stake in Ascendis Pharma A/S by 245.4% in the second quarter. Public Employees Retirement System of Ohio now owns 19,977 shares of the biotechnology company’s stock valued at $5,328,000 after acquiring an additional 14,193 shares in the last quarter. Seven Fleet Capital Management LP boosted its stake in Ascendis Pharma A/S by 114.8% in the first quarter. Seven Fleet Capital Management LP now owns 12,179 shares of the biotechnology company’s stock valued at $2,786,000 after acquiring an additional 6,509 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 148 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ASND shares. Jefferies Financial Group reiterated a “buy” rating and set a $333.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, August 13th. Oppenheimer reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Morgan Stanley raised their price target on Ascendis Pharma A/S from $256.00 to $275.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Barclays cut their price target on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Finally, Evercore reiterated an “outperform” rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Buy” and an average price target of $302.68.

Get Our Latest Stock Report on Ascendis Pharma A/S

Ascendis Pharma A/S Trading Down 0.6%

NASDAQ ASND opened at $247.91 on Friday. The firm’s fifty day moving average is $255.74 and its two-hundred day moving average is $239.08. Ascendis Pharma A/S has a one year low of $186.05 and a one year high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The firm has a market cap of $15.46 billion, a PE ratio of 19.23 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last announced its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Analysts expect that Ascendis Pharma A/S will post 3.9 earnings per share for the current year.

Key Headlines Impacting Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

Positive Sentiment: HC Wainwright initiated coverage of Ascendis Pharma with a Buy rating and a $345 price target, implying approximately 39% potential upside from the referenced share price. The bullish stance provides positive analyst support for ASND. HC Wainwright initiates coverage
Positive Sentiment: HC Wainwright analyst M. Kapoor projected Ascendis Pharma will earn $3.93 per share in fiscal 2026, broadly above the cited consensus estimate of $3.90, and expects quarterly EPS of $1.16 in Q3 2026 and $1.66 in Q4 2026. HC Wainwright FY2026 estimates
Positive Sentiment: The firm forecast substantial earnings growth in 2027, with quarterly EPS estimates rising from $1.76 in Q1 to $4.42 in Q4, resulting in projected full-year EPS of $11.88. If achieved, that would represent a significant improvement over the 2026 forecast and supports the analyst’s optimistic valuation. HC Wainwright FY2027 estimates

Insider Transactions at Ascendis Pharma A/S

In related news, Director Jean Jacques Bienaime acquired 2,000 shares of Ascendis Pharma A/S stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $246.33 per share, with a total value of $492,660.00. Following the purchase, the director directly owned 2,900 shares in the company, valued at approximately $714,357. The trade was a 222.22% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 40.00% of the stock is owned by company insiders.

Ascendis Pharma A/S Company Profile

(Free Report)

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.